NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Price, News & Analysis

Halozyme Therapeutics logo
$95.53 -0.97 (-1.00%)
As of 11:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Halozyme Therapeutics Stock (NASDAQ:HALO)

Advanced

Key Stats

Today's Range
$95.20
▼
$97.01
50-Day Range
$96.50
▼
$131.18
52-Week Range
$61.22
▼
$134.00
Volume
410,640 shs
Average Volume
1.98 million shs
Market Capitalization
$10.89 billion
P/E Ratio
24.31
Dividend Yield
N/A
Price Target
$108.18
Consensus Rating
Hold

Company Overview

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners. Its work centers on making selected injectable treatments available through alternative routes of administration.

AI Generated. May Contain Errors.

Halozyme Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

HALO MarketRank™: 
4.26171823131 of 5 stars

Halozyme Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 61st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Halozyme Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on no strong buy ratings, 7 buy ratings, 5 hold ratings, and 1 sell rating.

  • Upside Potential

    Halozyme Therapeutics has a consensus price target of $108.18, representing about 11.9% upside from its current price of $96.67.

  • Amount of Analyst Coverage

    Halozyme Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Halozyme Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Halozyme Therapeutics are expected to grow by 17.51% in the coming year, from $8.34 to $9.80 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Halozyme Therapeutics is 24.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.13.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Halozyme Therapeutics is 24.61, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.31.

  • Price to Earnings Growth Ratio

    Halozyme Therapeutics has a PEG Ratio of 0.38. PEG Ratios below 1 indicate that a company could be undervalued.

  • Percentage of Shares Shorted

    12.28% of the float of Halozyme Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Halozyme Therapeutics has a short interest ratio ("days to cover") of 6.81.
  • Change versus previous month

    Short interest in Halozyme Therapeutics has recently decreased by 0.03%, indicating that investor sentiment is improving.
  • Dividend Yield

    Halozyme Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Halozyme Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Halozyme Therapeutics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Halozyme Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    Only 13 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,346,093.00 in company stock.

  • Percentage Held by Insiders

    2.50% of the stock of Halozyme Therapeutics is held by insiders.

  • Percentage Held by Institutions

    97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Halozyme Therapeutics' insider trading history.
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HALO Stock News Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
Comparing Soligenix (NASDAQ:SNGX) & Halozyme Therapeutics (NASDAQ:HALO)
Halozyme Therapeutics (NASDAQ:HALO) Cut to "Hold" at Zacks Research
See More Headlines

HALO Stock Analysis - Frequently Asked Questions

Halozyme Therapeutics' stock was trading at $67.30 at the beginning of 2026. Since then, HALO stock has increased by 43.6% and is now trading at $96.6740.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.09. The company's quarterly revenue was up 39.1% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.

Halozyme Therapeutics' top institutional shareholders include Boston Partners (2.42%), Congress Asset Management Co. (2.01%), First Trust Advisors LP (1.59%) and William Blair Investment Management LLC (1.42%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Bernadette Connaughton, Jeffrey William Henderson, Nicole Labrosse, Mahesh Krishnan, Cortney Caudill and Cortney Caudill.
View institutional ownership trends
.

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Micron Technology (MU), Gilead Sciences (GILD), Intel (INTC), Palantir Technologies (PLTR) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/05/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:HALO
CIK
1159036
Employees
423
Year Founded
1998

Price Target and Rating

High Price Target
$149.00
Low Price Target
$56.00
Potential Upside/Downside
+12.8%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.93
Trailing P/E Ratio
24.41
Forward P/E Ratio
9.79
P/E Growth
0.38
Net Income
$316.89 million
Net Margins
26.93%
Pretax Margin
36.34%
Return on Equity
751.81%
Return on Assets
23.84%

Debt

Debt-to-Equity Ratio
13.50
Current Ratio
3.88
Quick Ratio
3.60

Sales & Book Value

Annual Sales
$1.40 billion
Price / Sales
7.83
Cash Flow
$4.55 per share
Price / Cash Flow
21.10
Book Value
($0.48) per share
Price / Book
-199.85

Miscellaneous

Outstanding Shares
114,010,000
Free Float
111,160,000
Market Cap
$10.94 billion
Optionable
Optionable
Beta
0.92

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:HALO) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners